A group of campaigners that includes Professor Stephen Hawking has been given the green light to challenge a government policy in court, which, they argue, could lead to privatisation of the NHS.
News
Evonetix raises £9m for novel gene synthesis tech
Cambridge, UK-based Evonetix has raised £9 million to help fuel the advance of its technology designed to enable scalable and high-fidelity gene synthesis.
My mHealth, LumiraDx form digital health partnership
My mHealth and LumiraDx Care Solutions have partnered to offer digital self-care to millions of patients in the UK, combining the groups’ expertise in clinical management software and digital technology.
Breakthrough status for Roche’s autism drug
Roche’s balovaptan has picked up a Breakthrough Therapy Designation in the US for its potential as a treatment for people with autism spectrum disorder (ASD), potentially placing the drug on a faster path to market.
AZ’ triple combo COPD inhaler hits PhIII targets
AstraZeneca recently unveiled top-line trial data backing use of an experimental triple combination therapy being developed for use with its Aerosphere technology in patients with chronic obstructive pulmonary disease (COPD).
Cambridge Uni launches £42m NHS care research institute
The University of Cambridge is launching a new, £42-million research institute, tasked with gathering evidence to better support decisions on improving NHS care and organisation.
EU clears MSD’s Prevymis for CMV prevention
European regulators have approved MSD’s Prevymis for the prevention of cytomegalovirus (CMV) reactivation and disease in prone adults who have received an allogeneic haematopoietic stem cell transplant (HSCT).
Survey reveals low awareness of kidney cancer
A charity survey has highlighted an “urgent need” for earlier diagnosis of kidney cancer, revealing that, in 51 percent of cases, the disease is detected from scans relating to other health conditions.
Sanofi snaps up Ablynx for 3.9bn euros
Sanofi has announced its intention to buy Belgian drugmaker Ablynx via a deal valued at around 3.9 billion Euros, beating Novo Nordisk to the finish line.
Brexit Alliance calls for Brexit deal on medicines regulation
The Brexit Health Alliance is again warning that medicines supply in the UK is in danger of being disrupted if the issue of co-operative regulation is not addressed during Brexit negotiations.
EU advisors reject Santhera’s Raxone for muscular dystrophy
Santhera’s attempt to win approval for Raxone as a treatment for Duchenne Muscular Dystrophy (DMD) in Europe has hit a giant setback after receiving a negative opinion from European Medicines Agency advisors.
US clears new option for gastroenteropancreatic tumours
US regulators have cleared the use of Novartis group Advanced Accelerator Applications’ Lutathera to treat certain gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Seven medicines leap closer to EU approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has put forward seven new medicines for approval in the region, including new treatment options for haemophilia A, diabetes, and a very rare genetic disorder.
Scotland’s Synpromics expands gene therapy work with UCL deal
Edinburgh, Scotland based Synpromics has teamed up with UCL Great Ormond Street Institute of Child Health to develop novel gene therapies for diseases affecting the haematopoietic system.
Takeda/Zinfadel terminate late-stage Alzheimer’s study
Alzheimer’s disease research has taken another hit with the termination of a Phase III study assessing the effect of diabetes drug pioglitazone on mild cognitive impairment (MCI) in patients with the condition.
